These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9894975)

  • 1. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats.
    Bemana I; Nagao S
    Neurosurgery; 1999 Jan; 44(1):148-54; discussion 154-5. PubMed ID: 9894975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema.
    Bemana I; Takahashi E; Nakamura T; Kuyama H; Nagao S
    Acta Neurochir Suppl; 1997; 70():194-7. PubMed ID: 9416320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of vasogenic brain edema with arginine vasopressin receptor antagonist--an experimental study.
    Nagao S; Kagawa M; Bemana I; Kuniyoshi T; Ogawa T; Honma Y; Kuyama H
    Acta Neurochir Suppl (Wien); 1994; 60():502-4. PubMed ID: 7976630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine vasopressin receptor antagonists for treatment of vasogenic brain edema: an experimental study.
    Kagawa M; Nagao S; Bemana I
    J Neurotrauma; 1996 May; 13(5):273-9. PubMed ID: 8797177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an orally active vasopressin V1 receptor antagonist.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular responses to vasopressin antagonists in man and rat.
    Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
    Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268.
    Li X; Kribben A; Wieder ED; Tsai P; Nemenoff RA; Schrier RW
    Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
    Nishikimi T; Kawano Y; Saito Y; Matsuoka H
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of brain edema, blood-brain barrier breakdown, and injury volume by ifenprodil, a polyamine-site N-methyl-D-aspartate receptor antagonist, after experimental traumatic brain injury in rats.
    Dempsey RJ; Başkaya MK; Doğan A
    Neurosurgery; 2000 Aug; 47(2):399-404; discussion 404-6. PubMed ID: 10942013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPC-21268, a vasopressin V1 antagonist, produces hypotension in spontaneously hypertensive rats.
    Yamada Y; Yamamura Y; Chihara T; Onogawa T; Nakamura S; Yamashita T; Mori T; Tominaga M; Yabuuchi Y
    Hypertension; 1994 Feb; 23(2):200-4. PubMed ID: 8307629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats.
    Rosenberg GA; Scremin O; Estrada E; Kyner WT
    Stroke; 1992 Dec; 23(12):1767-73; discussion 1773-4. PubMed ID: 1448828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.
    Imaizumi T; Harada S; Hirooka Y; Masaki H; Momohara M; Takeshita A
    Hypertension; 1992 Jul; 20(1):54-8. PubMed ID: 1319959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of arginine vasopressin receptor antagonist on the rat cold-injured brain].
    Kagawa M; Nagao S
    No Shinkei Geka; 1993 Dec; 21(12):1103-7. PubMed ID: 8259220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
    Masaki H; Imaizumi T; Harada S; Momohara M; Hirooka Y; Takeshita A
    Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of traumatic brain edema by multiple doses of mannitol.
    von Berenberg P; Unterberg A; Schneider GH; Lanksch WR
    Acta Neurochir Suppl (Wien); 1994; 60():531-3. PubMed ID: 7976640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis.
    Kurihara I; Saito T; Obara K; Shoji Y; Hirai M; Soma J; Sato H; Imai Y; Abe K
    Nephron; 1996; 73(4):629-36. PubMed ID: 8856262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.
    Yamamura Y; Ogawa H; Chihara T; Kondo K; Onogawa T; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
    Science; 1991 Apr; 252(5005):572-4. PubMed ID: 1850553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cold injury-induced brain edema with a nonspecific matrix metalloproteinase inhibitor MMI270 in rats.
    Kawai N; Kawanishi M; Okada M; Matsumoto Y; Nagao S
    J Neurotrauma; 2003 Jul; 20(7):649-57. PubMed ID: 12908926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.